Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 6OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2873Carcinoma, Non-Small-Cell Lung 2426Breast Neoplasms 2067Colorectal Neoplasms 1245Neoplasm Metastasis 1231Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 757Pancreatic Neoplasms 752Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 435Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 409Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Multi-centric Castleman's Disease × Clear all
NCT01024036 2018-03-21

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Janssen Research & Development, LLC

Phase 2 Completed
79 enrolled 20 charts

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡